ArticleAmerican journal of translational research2025
Repeated low-intensity red light therapy for childhood myopia: a retrospective cohort study.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the efficacy and safety of repeated low-intensity red light (RLRL) therapy in slowing myopia progression and improving accommodative function in children.
methodsThis retrospective cohort study reviewed electronic medical records of 202 myopic children aged 6-12 years treated at Ganzhou People's Hospital between October 2022 and October 2024. Participants were assigned to an RLRL group (n = 101; 650 nm, 1600 lx, 3 min, twice daily) or a control group (n = 101; single-vision spectacles only). Primary outcomes included axial length and spherical equivalent refraction. Secondary outcomes were uncorrected and best-corrected visual acuity, macular choroidal thickness, accommodative amplitude and facility, intraocular pressure (IOP), and corneal endothelial cell density (ECD).
resultsBaseline demographics and ocular characteristics were comparable between groups (all P > 0.05). Up to 12 months, the RLRL group exhibited significantly less axial elongation and myopic refractive progression (P < 0.05 from 6 months onward), greater improvement in uncorrected visual acuity, thicker macular choroid, and enhanced accommodative function compared to controls (all P < 0.05). No significant between-group differences were observed in IOP or corneal ECD (both P > 0.05).
conclusionRLRL therapy significantly slowed myopia progression and improved visual and accommodative function in children over 12 months, with no major safety concerns. These findings support RLRL as a promising, safe intervention for pediatric myopia control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.